Major Hydroxychloroquine Study Retracted: ‘We Deeply Apologize’

Sunday, 07 Jun, 2020

What Exactly is Hydroxychloroquine, How Does it Work in Treating COVID-19?. The report said that scientists from Harvard Medical School in the USA wanted the paper to be retracted because they were not granted some underlying data for research.

Mentioning the limitations of the research, they said the median age in their study was about the same age as that in other studies of hospitalised patients - 70 years - but since the patients were older, the findings might not apply to younger people with Covid-19.

Authors of both papers said they could no longer vouch for the data's accuracy.

"Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements", the statement read.

On Wednesday the Lancet published an expression of concern about the paper, and and said the co-authors of the study who were not from Surgisphere had commissioned an independent audit into the provenance and veracity of the data.

Since this article was published, a statement from the chief investigators of the RECOVERY trial has confirmed that they will be stopping the enrolment of patients to the hydroxychloroquine arm of the trial, after preliminary results showed that the drug had no benefit for patients hospitalised with COVID-19.

Martin Landray, professor of epidemiology at Oxford, added: 'If you're admitted to hospital with Covid - you, your mother or anyone else - hydroxychloroquine is not the right treatment.

Following the study, the World Health Organization paused enrolling patients in clinical trials testing hydroxychloroquine, although this week the organization said it resumed the trials.

On Friday, results from a fourth randomized controlled trial - carefully designed human experiments considered the most robust form of clinical investigation - showed it had no impact against the virus.

Aside from the New England Journal of Medicine and The Lancet, the research was also widely published by major media organisations across the world, with a lot of them citing both organisation's long-standing credibility in the publication of scientific breakthroughs.

The anti-malarial drug has been controversial in part due to support from Trump, as well as implications of the study published in British journal The Lancet last month, which led several COVID-19 studies to be halted. Hydroxychloroquine was championed by US President Donald Trump.

A separate clinical trial on Wednesday in the United States and Canada found that taking hydroxychloroquine shortly after being exposed to COVID-19 does not work to prevent infection significantly better than a placebo.

The second study has also used data provided by Surgisphere to conclude that certain blood pressure drugs didn't appear to increase the risk of coronavirus patients dying.

"One of the core principals at Surgisphere is based around data integrity". According to the researchers, the findings don't provide insight into the use of these drugs in the outpatient setting or as prophylaxis.